BIOCRYST PHARMACEUTICALS INC — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
BioCryst reported Q2 2026 total net revenue of $218.3M (+34% YoY), with ORLADEYO net revenue of $158.2M (+1% YoY). Operating profit was $98.5M GAAP and $113.2M non-GAAP. The company completed enrollment in navenibart pivotal trial (ALPHA-ORBIT) and launched ORLADEYO oral pellets for pediatric patients on August 3, 2026. Key deal: licensed navenibart European rights to Neopharmed Gentili for $70M upfront plus up to $275M in milestone payments and 18–30% tiered royalties; recognized $55.7M revenue in Q2. Raised FY2026 total revenue guidance to $690–$715M (from $635–$660M), maintained ORLADEYO guidance at $625–$645M, and lowered non-GAAP operating expense guidance to $420–$440M.
Why this rating
Strong Q2 execution, pipeline progress, and upside guidance raise offset by $698M in-process R&D charge from Astria acquisition and $395M secured debt. Core business is growing; navenibart deal ($70M upfront) is material but licensing (not internal development) and ≈3.7% of market cap. Moderate trajectory impact for $1.9B company.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.